Skip to content
Screener

LB Pharmaceuticals Inc LBRX Debt-to-equity

Debt-to-equity at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
1.9×-0.9×
Alkermes logo
AlkermesALKS
0.9×+0.8×
MapLight Therapeutics, Inc. logo
MapLight Therapeutics, Inc.MPLT
0×—
Alto Neuroscience logo
Alto NeuroscienceANRO
0.1×-0.1×
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
0.1×0.0×
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
0×0.0×

Other financials

Income statement

See full
Net income-$19.1M-259%
EPS (diluted)-$0.67+95.5%

Balance sheet

See full
Cash & equivalents$320.7M—
Total debt$3.5M—
Total equity$378.7M+481%
Total assets$393.5M—

Cash flow

See full
Operating cash flow-$23.3M-187%
CapEx$32.0K+52.4%
Free cash flow-$23.3M-186%

Valuation

See full
Market cap$1.38B+309%
Enterprise value$1.06B—

Returns & leverage

See full
Return on equity-27.9%—
Current ratio35.7×—

Where this comes from

Calculated from LB Pharmaceuticals Inc’s reported figures.

total debt/total stockholders equity=0×

Based on the most recent quarter.

The source filing: LB Pharmaceuticals Inc’s 10-Q, filed May 12, 2026. Open the filing →

Filed
May 12, 2026, 4:31 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-219607

FAQ

What is LB Pharmaceuticals Inc's debt-to-equity?
LB Pharmaceuticals Inc (LBRX) reported debt-to-equity of 0× in Q1 2026.
What does debt-to-equity mean?
Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.

Ask your AI about LB Pharmaceuticals Inc's debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude